SCHEMBL1115799

SCHEMBL1115799

CCCCCCCCCCCCCC(C)C(=O)O

nearest known ligand 0.80

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.80
GPR84 Q9NQS5 7/20 0.61
CA1 P00915 2/20 0.61
FFAR1 O14842 2/20 0.61
MAPT P10636 1/20 0.59
LCK P06239 1/20 0.59
PPARD Q03181 1/20 0.59
ZDHHC20 Q5W0Z9 1/20 0.59
ZDHHC2 Q9UIJ5 1/20 0.59
FFAR4 Q5NUL3 1/20 0.55
BLM P54132 1/20 0.54
LTA4H P09960 1/20 0.53
FAAH O00519 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6657056 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL545070 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
Dodecane SCHEMBL14691319 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL194398 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL247871 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL22023412 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL7080552 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL7146627 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL2054033 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT
SCHEMBL277986 1.00 ACE2 (0.80) ACE2GPR84CA1FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262368-B1 WEARABLE PET DEVICES WITH PASSIVE DIFFUSION OF SEMIOCHEMICAL COMPOSITIONS VIRBAC (FR) 2026-01-28 EP claimed
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2020-10-06 US claimed
EP-3661600-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME Epitracker, Inc. (US) 2020-06-10 EP claimed
US-20180148744-A1 BIOLOGICAL METHODS FOR PREPARING 3-HYDROXYPROPIONIC ACID VERDEZYNE INC (US) 2018-05-31 US claimed
EP-2644185-B1 THICK CLEANING COMPOSITION SUZHOU ELECO CHEMICAL IND CO LTD (CN) 2018-04-25 EP claimed
CN-103338743-B A kind of Cleasing compositions of stiff SUZHOU YUANSUJI CHEMICAL INDUSTRY Co.,Ltd. (CN) 2016-06-01 CN claimed
US-9283442-B2 Golf ball DUNLOP SPORTS CO. LTD. (JP) 2016-03-15 US claimed
EP-2644185-A1 THICK CLEANING COMPOSITION Suzhou Yuansuji Chemical Industry Co., Ltd. (CN) 2013-10-02 EP claimed
US-20130251648-A1 THICK CLEANING COMPOSITION SUZHOU YUANSUJI CHEMICAL INDUSTRY CO., LTD. (CN) 2013-09-26 US claimed
WO-2013134656-A1 INDUCTION OF TH17 IMMUNE RESPONSE GENOCEA BIOSCIENCES, INC. (US) 2013-09-12 WO claimed
US-20050153869-A1 Fatty acids, soaps, surfactant systems, and consumer products based thereon THE PROCTER & GAMBLE COMPANY 2005-07-14 US claimed
US-5536436-A DETERGENT, LIPOLYTIC ENZYME, BUILDERS AND SOAPS THE PROCTER & GAMBLE COMPANY (US) 1996-07-16 US claimed
WO-1995033041-A1 LIQUID LAUNDRY DETERGENT COMPOSITIONS CONTAINING LIPOLYTIC ENZYME AND SPECIALLY SELECTED SOAPS THE PROCTER & GAMBLE COMPANY (US) 1995-12-07 WO claimed
WO-1995033044-A1 LIQUID LAUNDRY DETERGENT COMPOSITIONS COMPRISING SPECIALLY SELECTED SOAPS THE PROCTER & GAMBLE COMPANY (US) 1995-12-07 WO claimed
US-5380892-A Clathrates HOECHST AKTIENGESELLSCHAFT (DE) 1995-01-10 US claimed
CN-122070276-A Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same 人类生物科学股份有限公司 2026-05-19 CN disclosed
US-12564879-B2 Copper paste for joining, method for manufacturing joined body, and joined body RESONAC CORPORATION (JP) 2026-03-03 US disclosed
US-4544794-A NEO ACID AND FATTY ACID ATLANTIC RICHFIELD COMPANY (US) 1985-10-01 US disclosed
EP-0108645-A2 Novel ailanthone derivative SUNTORY LIMITED (JP) 1984-05-16 EP disclosed
US-4440666-A Method of making corrosion inhibiting polyamine amides, the amides, and use therefor ATLANTIC RICHFIELD CO. (US) 1984-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome FABP1, FASN, GPR119 ACE2 1787/4885GPR84 598/4885CA1 3525/4885
US-12564879-B2 Copper paste for joining, method for manufacturing joined body, and joined body DCX, DNAJA2, DNAJA1 ACE2 2558/4885GPR84 4417/4885CA1 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.